An uncontrolled trial of pefloxacin in the retreatment of patients with pulmonary tuberculosis.
To study the role of Pefloxacin in the retreatment of pulmonary tuberculosis. 14 cases of sputum smear-positive tuberculosis were given pefloxacin in doses of 400 mg daily, along with isoniazid and thioacetazone plus additional drugs wherever indicated. They were followed and assessed by sputum smear microscopy and chest X-ray regularly for the total duration, which ranged from 15-18 months. 10 of the patients completed treatment and achieved a satisfactory response in the form of persistent sputum, negativity and radiologically quiescent disease. Two developed serious side-effects and had to discontinue medication. One patient failed on therapy as evidenced by persistent sputum positivity at 6 months. Pefloxacin may have a role in the retreatment of pulmonary tuberculosis along with other drugs, as a companion drug in selected cases. The other advantages are the low cost of treatment and high safety profile.